15th December 2017, Volume 130 Number 1467

Ian Sheerin

New Zealand and Australia have a major hepatitis C virus (HCV) epidemic which is receiving inadequate public health policy attention. Currently there is a mix of factors that offer the potential for a major public health success in terms of controlling and even possibly eliminating the epidemic, however health policies would need significant ongoing improvement to achieve this. HCV imposes a substantial burden on the population and the health system. Evidence indicates that approximately 54,000 New Zealanders and 230,000 Australians have chronic HCV and many will develop liver cirrhosis and hepatocellular carcinoma (HCC).1,2 This epidemic has spanned decades and is international with estimates of up to 170 million people worldwide having HCV infection.

Current situation

HCV infection is potentially preventable and also in 2016 new direct acting anti-viral medicines (DAAs) were publicly funded in both New Zealand and Australia. These DAAs are potentially a game-changing improvement as they offer cure rates of 95% with few side-effects, with only 12 weeks of treatment, much of which can be provided in primary care.3,4 This contrasts with previous interferon-based treatments that had poorer outcomes, major side-effects which led to adherence problems, an HCV community view that the “treatment was worse than the disease” and consequent low uptake. Hence the new DAAs offer a major step forward and they are rapidly gaining a good reputation among people infected with HCV who are now hearing good news stories from their peers who have experienced the new treatments. But until 2016, treatment uptake was low. In Australia, 1 to 2% of the chronically infected initiated specific HCV treatments each year, while in New Zealand fewer than 10% had accessed treatment by 2014.2,5 Treatment uptake has improved following the public funding of DAAs in 2016 in both countries. Pharmac reported that by July 2017, 2,000 people in New Zealand had been treated with the new DAAs.6 Australia has made more progress, as from March to December 2016 more than 32,500 people had initiated treatment with DAAs.7

There is some opinion that a reduction in stigmatisation is now enabling more people to present for treatment.

New treatments

Recommended treatments are genotype specific. In both countries the prevalent genotypes (Gt) are Gt1 (50–55% of cases) and Gt3 (35–40%).3 Access to the new DAA medicines is better in Australia where DAAs were approved and publicly funded in 2016 for both Gt1 and Gt3. New Zealand is currently behind as DAAs were publicly funded in 2016 for Gt1, while DAAs for Gt3 are not yet publicly funded unless a special case is made on an individual patient basis.4 Importing a DAA privately directly from the drug company would cost approximately $NZ75,000, so some people have been accessing a buyers club to obtain the medicine at a more affordable private cost of between $NZ1,600–4,000.8 The high prices proposed by the drug companies for government funding for the new DAAs has been a barrier to their being adopted sooner.

For most people the new DAA medicines can be prescribed and managed in primary care, by a GP in consultation with a specialist. However, if the infection has progressed to liver cirrhosis, treatment requires specialist consultation and management, so there has been considerable effort to develop treatment guidelines and coordination between primary- and secondary-care services.3,4 Recent trends to encourage more treatment in the primary care sector are creating more potential for widespread early intervention and prevention of complications and costs of advanced liver disease.3,9 Although there is some evidence of possible recent declines in HCV incidence and prevalence in some countries10 the overall burden of liver disease is increasing, which is placing increased pressure on specialist hospital care, liver transplants and public health resources.5,11 Specific strategies are required to control and reduce this disease burden.

Causes and prevention

In recent decades, 95% of new HCV infections in western countries have been caused by injecting drug use and sharing of injecting equipment.11,12,13 Other risk factors include previous blood transfusion, history of imprisonment, tattoos, body piercing, contact with blood and blood products. Studies suggest that in Australia and New Zealand, immigration and mother-to-child transmission account for relatively few cases.10 Sexual transmission is not significant for HCV, except where there is HIV coinfection. The epidemic varies in different parts of the world, particularly in less developed countries with less resourced health systems and where safe blood supplies may not be available.

Both voluntary and health sector agencies have invested considerably in harm reduction strategies, generating blood safety awareness, the importance of safe injection practices, needle exchanges and avoiding sharing of needles. However, there are recent reports of increases in injecting drug use and associated harms. In the US, studies indicate from 2006–12 there was a nationwide increase in HCV infections and injecting drug use.14 This has occurred in the context of a nationwide epidemic of opioid use and drug overdose deaths.15,16 In Australia, New Zealand and the US, there is concern over the increasing injecting of oxycodone, other prescription opioids and methamphetamine.17–22 In Australia, studies indicate there has been an increase in opioid prescribing and in opioid poisoning since at least 2002.17,19,21 Similar trends have been reported for the UK, US and Canada.18 Hence, the evidence of any possible reduction of HCV incidence is at best uncertain and in fact it indicates that drug-related harm is increasing. Therefore, continuing investment should be made in policies and services aimed at reducing such harm, including HCV infections.

People with a history of injecting drug use (PWID) are generally on lower incomes, are often difficult to engage in general primary care services, tend to be marginalised and stigmatised. Similarly, surveys of prisoners and ex-prisoners in both Australia and New Zealand have found HCV prevalence ranging upwards from approximately 25% with higher prevalence in those with a history of injecting drug use.10,23 Prevention of drug-related harm and blood-borne viruses (BBV) requires multi-faceted harm reduction policies, including alcohol and drug services, needle exchanges and creating much greater awareness of BBVs and how to prevent them. This includes a collaborative partnership with voluntary agencies who are able to engage and communicate with marginalised people such as PWID, prisoners and ex-prisoners.15,24 Regrettably, in New Zealand voluntary agencies with these aims have been operating with very limited government funding. As those infected with HCV tend to have lower incomes, widening access to treatment needs to include reducing financial barriers to access such as patient copayments, currently around an average $40 per consultation.

Discussion and conclusion

The outlook for people with chronic HCV infection has improved dramatically in 2016, with improved access to effective medicines that offer every likelihood of a cure for most. However, in both Australia and New Zealand, many infections remain undiagnosed, the majority have not yet been treated and the burden of chronic liver disease is growing. This will place increasing strain on health services. An estimated 5–10% of cases of chronic HCV develop to cirrhosis within 20 years from the time of infection,25 and approximately 3–5% per annum of those develop HCC. More rapid rate of progression to advanced liver disease is associated with other factors such as coinfection with hepatitis B virus and/or heavy alcohol use. Cirrhosis involves complications that necessitate hospital admissions, and a portion will require liver transplants. This disease burden is potentially preventable and with specific public health policies the HCV epidemic could be contained and reduced. The key elements that are needed include:

  • Recognition and willingness at higher levels of government and the health sector;
  • Collaborative harm reduction policies to reduce drug-related harms;
  • Expanding access to diagnosis and treatment, including drug and alcohol services and primary care. Education of primary care professionals is important. Nurse-led HCV clinics and ways of paying for them should be promoted. Treatment for prisoners and ex-prisoners should be provided. Cirrhosis necessitates regional networks with capacity for specialist management;
  • Investment and public funding of DAAs for all HCV genotypes, with copayments affordable for lower income people;
  • Greater investment in prevention and communication strategies to address key populations and including awareness programmes through needle exchanges, alcohol and drug services, prisons and rehabilitation services;
  • Management of the overall strategy at national and regional government levels, including regular review of key indicators.

Both Australia and New Zealand have published HCV strategies,11,26 with much emphasis on improving the coordination of treatment. Shorter courses of treatment, fewer side-effects and options for general practitioners to be involved with treatment all offer the potential to increase capacity and numbers treated.27,28 Australia is making more progress in-so-far that it has achieved a higher diagnosis rate, with an estimated 80% of infections having been diagnosed.11 In contrast, only approximately half of infected New Zealanders have been diagnosed.2 Australia has also funded access to new DAA treatments for all HCV genotypes, whereas in New Zealand access to DAAs is currently limited to patients with genotype 1. Progress in Australia has prompted discussion that it could potentially be the first country in the world to attain the World Health Organization’s goal of eliminating viral hepatitis as a public health threat by 2030 (defined as a 65% reduction in mortality and a 90% reduction in new infections compared with the 2015 baseline).13,28

However, improved control of the HCV epidemic requires preventive strategies which engage with higher risk populations. Regrettably, government strategies in both New Zealand and Australia fall short on prevention. It would be a significant advance to get more people through treatment, but unless new infections can also be prevented, the HCV epidemic will continue to impose an increasing burden on the health system. A key to prevention is to reduce infections associated with injecting drug use, while also addressing other risk factors such as tattooing, body piercing and barriers to access. There is good evidence that needle exchanges have been effective in helping to control both HIV and HCV11,29 and that they are perceived as engaging successfully with PWID, who tend to be marginalised and often do not engage with conventional health services. Government strategies need to emphasise greater collaboration with such community agencies who can effectively engage higher risk populations, convey preventive measures and assist with accessing heathcare. In Australia, advocacy by non-government agencies has resulted in more funding and emphasis on public awareness and case detection.

Gane and colleagues2 have modelled the potential for HCV infection to be eliminated from New Zealand within our lifetime. Access to the new DAAs is a key ingredient but they also noted the requirement for ongoing measures to prevent new infections, improve community awareness, increase detection and to provide programmes for people at high risk of infection such as PWID and prisoners. Australian experts have also recommended similar requirements.24 Agencies working with these populations are not currently able to access sufficient funding to provide adequate ongoing preventive services.

There is potential for a major public health success in controlling the HCV epidemic, but this will require investment in an improved, coordinated, collaborative strategy, including renewed emphasis on prevention as well as the above key ingredients.

Summary

There is potential to control and possibly eliminate the hepatitis C virus epidemic in New Zealand and in Australia. It can cause more advanced liver disease, liver cirrhosis and liver cancer but it is potentially preventable and curable. There is inadequate public health policy attention to preventing new infections and reducing barriers. There is a need for increased investment to reduce barriers, improve coordination and community awareness and to collaborate to engage with the affected population who can be stigmatised and marginalised.

Abstract

New Zealand and Australia both now have the potential for a major public health success in controlling the hepatitis C virus epidemic. The burden of advanced liver disease and drug-related harm is increasing. However, a new range of anti-viral therapies have become available which offer a potential cure for most people with few side-effects. The epidemic is potentially preventable and hepatitis C is now curable. Although public health strategies for blood-borne viruses have been updated, they fall short of what is needed and should be upgraded with more emphasis on prevention, in order to achieve control of this epidemic.

Author Information

Ian Sheerin, Population Health, University of Otago, Christchurch. 

Correspondence

Dr Ian Sheerin, Population Health, University of Otago, 34 Gloucester St, Christchurch 8140.

Correspondence Email

ian.sheerin@otago.ac.nz

Competing Interests

Dr Sheerin is Chairman of the Hepatitis C resource Centre Trust (Te Waipounamu) Inc, which has previously received New Zealand government funding to undertake educational activities to increase awareness about the causes and prevention of blood borne virus transmission.

References

  1. Kirby Institute. National blood-borne viruses and sexually transmissible infections surveillance and monitoring report, 2016. The Kirby Institute, UNSW Sydney, NSW. Available on http://kirby.unsw.edu.au Accessed June, 2017.
  2. Gane E, Stedman C, Brunton C, et al. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand. New Zealand Medical Journal 2014; 127(1407). http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2014/vol-127-no-1407/6390
  3. Thompson AJV on behalf of the Gastroenterological Society of Australia. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Medical Journal of Australia 2016; 204(7). DOI:10.5694/mja16.00106
    http://www.nzsg.org.nz/cms2/guidelines/
  4. Gane E, Stedman C. NZ Society of Gatroenterology HCV treatment guidelines. November 2016 update.
  5. Snow K, Scott N, Clothier HJ, et al. Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001–2012: a multi-level modelling analysis. Australian and New Zealand Journal of Public Health 2017; 41:193–8;DOI:10.1111/1753-6405.12560. Accessed April 2017.
  6. PHARMAC. Hepatitis C Treatments. World Hepatitis day – check and treat. 2017; http://www.pharmac.govt.nz/medicines/my-medicine-has-changed/ Accessed 2 Aug, 2017.
  7. The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia (Issue 7). The Kirby Institute, UNSW Sydney, NSW, Australia. July 2017. Available at http://unsw.edu.au/report/monitoring-hepatitis-c-treatment-uptake-australia-issue-7-july-2017 
  8. http://fixhepc.com/hcv. Accessed August 2017 
  9. Best Practice. The treatment of hepatitis C has changed. Best Practice Journal 2016; Issue77SE. http://www.bpac.org.nz
  10. Hellard M, Horyniak D, Aitken C. Global epidemiology of hepatitis C. 2009. Chapter 5 in Dore G, Temple-Smith M, Lloyd A (eds). Hepatitis C an expanding perspective. 2009; IP Communications: Melbourne.
  11. Commonwealth of Australia. Fourth national hepatitis C strategy 2014–2017. Australian Government, Department of Health. Available on www.health.gov.au Accessed June 2017.
  12. Topp L, Maher L, Kaldor J. Transmission of hepatitis C virus. Chapter 6 in Dore G, Temple-Smith M, Lloyd A (eds). Hepatitis C an expanding perspective. 2009; IP Communications: Melbourne.
  13. World Health Organization. Global hepatitis report, 2017. Geneva: World Health Organization; 2017
  14.  Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injecting drug use among persons aged ≤30 years – Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. Morbidity and Mortality Weekly Report 2015, May 8/74(17); 453–458. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6417a2.htm Accessed 17 Jan, 2017.
  15. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths- United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2016; 65(50–51):1445–1451. http://www.cdc.gov/mmwr
  16. Meldrum ML. The ongoing opioid prescription epidemic: historical context. American Journal of Public Health 2016; 106; 8:1365–66. DOI: 10.2105/AJPH.2016.303297
  17. Berecki-Gisolf J, Hassani-Mahmooei B, Clapperton A, McClure R. Prescription opioid dispensing and prescription opioid poisoning: population data from Victoria, Australia 2006 to 2013. Australian and New Zealand Journal of Public Health 2017; 41:85–91. DOI: 10.1111/1753-6405.12568. Accessed Jan 2017. 
  18. Kim B, Nolan S, Lianping T. Addressing the prescription opioid crisis: potential for hospital-based interventions? Drug and Alcohol Review (March) 2017; 36:149–152. DOI: 10.1111/dar.12541
  19. Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. British J of Clinical Pharmacology 2014; 78:5:1159–1166. DOI:10.1111/bcp.12446 
  20. Karanges EA, Blanch B, Buckley NA et al. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. British J of Clinical Pharmacology 2016; 82:255–267. DOI:10.1111/bcp.12937
  21. Peacock A, Bruno R, Cama E, et al. Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. Drug and Alcohol Review 2015; 34;611–622. DOI:10.1111/dar.12279. Accessed Feb 2017.
  22. Wilkins C, Prasad J, Wong K, Rychert M. Recent trends in illegal drug use in New Zealand, 2006–2013. Social and Outcomes Research and Evaluation, School of Public Health, Massey University; Auckland, 2014.
  23. Butler T, Boonwaat L, Hailstone S, et al. The 2004 Australian prison entrants’ blood-borne virus and risk behaviour survey. Australian and New Zealand Journal of Public Health 2007; 31.1:44–50 
  24. Wallace J, Temple-Smith M. Elements of a co-ordinated response. Chapter 20 in Dore G, Temple-Smith M, Lloyd A (eds). Hepatitis C an expanding perspective. 2009; IP Communications: Melbourne.
  25. Thein H, Dore G. Natural history of hepatitis C virus infection. Chapter 4 in Dore G, Temple-Smith M, Lloyd A (eds). Hepatitis C an expanding perspective. 2009; IP Communications: Melbourne.
  26. Ministry of Health. Work in progress for improving hepatitis treatment services in New Zealand. Available on http://www.health.govt.nz/our-work/diseases-and-conditions/hepatitis-c. Accessed January 2017.
  27. Kaan IA, Jones T, McCaughan GW. Have we significantly underestimated the capacity in the Australian health system to treat chronic hepatitis C infection in an interferon-free era? Internal Medicine Journal 2017; 47;3:269–74. DOI: 10.1111/imj.13262 
  28. Sievert W. Interferon-free treatment for HCV infection: are we on the road to elimination? Internal Medicine Journal 2017; 47;3:247–49. DOI: 10.1111/imj.13354
  29. Lauzon C. Surveillance of HIV and hepatitis C prevalence among attendees of needle exchanges throughout New Zealand. 2010. Masters of Public Health Thesis, University of Otago, New Zealand.